Patents by Inventor Richard John Harrison
Richard John Harrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10593171Abstract: An anti-ligature alarm device, comprises a sensing unit and a control unit. The sensing unit detects an external force when the external force is applied to the sensing unit and also transmits a signal indicating an alarm condition. The control unit comprises a receiver which receives the signal on detection of the external force. The sensing unit also includes a power source and a controller and the sensing unit and control unit are wirelessly paired to each other. The sensing unit also comprises a boost module which maintains a voltage input from the power source to the controller. The control unit is wirelessly networked to an alert device and the anti-ligature alarm device further includes a pairing device which is used to pair the sensing unit and the control unit.Type: GrantFiled: January 21, 2019Date of Patent: March 17, 2020Assignee: Intastop LimitedInventors: Richard John Harrison, Daniel Lee Szlamp
-
Publication number: 20190266862Abstract: An anti-ligature alarm device, comprises a sensing unit and a control unit. The sensing unit detects an external force when the external force is applied to the sensing unit and also transmits a signal indicating an alarm condition. The control unit comprises a receiver which receives the signal on detection of the external force. The sensing unit also includes a power source and a controller and the sensing unit and control unit are wirelessly paired to each other. The sensing unit also comprises a boost module which maintains a voltage input from the power source to the controller. The control unit is wirelessly networked to an alert device and the anti-ligature alarm device further includes a pairing device which is used to pair the sensing unit and the control unit.Type: ApplicationFiled: January 21, 2019Publication date: August 29, 2019Inventors: Richard John Harrison, Daniel Lee Szlamp
-
Patent number: 9655897Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.Type: GrantFiled: March 3, 2016Date of Patent: May 23, 2017Assignee: Cellzome LimitedInventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
-
Publication number: 20160184307Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.Type: ApplicationFiled: March 3, 2016Publication date: June 30, 2016Inventors: Richard John HARRISON, Nigel RAMSDEN, Jeremy MAJOR, Adeline MOREL, Laura CONVERY, Mihiro SUNOSE, Rosemary LYNCH, Rita ADREGO, Alison JONES
-
Patent number: 9296725Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.Type: GrantFiled: May 23, 2013Date of Patent: March 29, 2016Assignee: Cellzome LimitedInventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
-
Patent number: 9242987Abstract: The invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: GrantFiled: October 19, 2010Date of Patent: January 26, 2016Assignee: Cellzome LimitedInventors: Nigel Ramsden, Richard John Harrison, Sally Oxenford, Kathryn Bell, Nelly Piton, Claudio Dagostin, Cyrille Broussard, Andrew Ratcliffe
-
Publication number: 20150166513Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.Type: ApplicationFiled: May 23, 2013Publication date: June 18, 2015Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
-
Publication number: 20140179664Abstract: The present invention relates to compounds of formula (I) wherein X1 to X5, Z1 to Z3, Y0, RY1, RY2 and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: July 24, 2012Publication date: June 26, 2014Applicant: Cellzome LimitedInventors: Jay Freeman, Valerie Reader, Glynn Addison, Nigel Ramsden, Jane Elizabeth Scanlon, Richard John Harrison
-
Publication number: 20130131043Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R1a, R1b have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: April 18, 2011Publication date: May 23, 2013Inventors: Richard John Harrison, Warren Miller, Sally Oxenford, Nigel Ramsden, Andrew Hobson
-
Publication number: 20120252779Abstract: The invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: October 19, 2010Publication date: October 4, 2012Inventors: Nigel Ramsden, Richard John Harrison, Sally Oxenford, Kathryn Bell, Nelly Piton, Claudio Dagostin, Cyrille Boussard, Andrew Ratcliffe
-
Publication number: 20120172384Abstract: The invention relates to compounds of formula (I) wherein R1 to R6 and T0 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70, Syk or JAK3 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: June 17, 2010Publication date: July 5, 2012Inventors: Mihiro Sunose, Jeremy Major, Richard John Harrison, Jay Freeman, Adeline Morel
-
Publication number: 20120172385Abstract: The invention relates to compounds of formula (I) wherein X1 to X3, R, R2 to R7 and AA have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: September 7, 2010Publication date: July 5, 2012Inventors: Richard John Harrison, Andrew Hobson, Nigel Ramsden
-
Publication number: 20120040955Abstract: The invention relates to compounds of formula (I) wherein AA, R2 to R7 and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as selective inhibitors of JAK3 over JAK2 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: April 9, 2010Publication date: February 16, 2012Inventors: Richard John Harrison, Andrew Hobson, Nigel Ramsden
-
Patent number: 8106236Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: GrantFiled: April 19, 2007Date of Patent: January 31, 2012Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Yan Zhang, Chih Yung Ho
-
Publication number: 20110098288Abstract: The invention relates to compounds of formula (I) wherein R1 to R9 and R4a have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: March 10, 2009Publication date: April 28, 2011Inventors: Jeremy Major, Richard John Harrison, Nigel Ramsden, David Middlemiss, Ulrich Kruse, Gerard Drewes
-
Publication number: 20110028405Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, R3, R8, R9 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: December 17, 2008Publication date: February 3, 2011Inventors: Richard John Harrison, Jeremy Major, David Middlemiss, Nigel Ramsden, Ulrich Kruse, Gerard Drewes
-
Patent number: 7825160Abstract: The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: GrantFiled: October 21, 2005Date of Patent: November 2, 2010Assignee: Cellzome LimitedInventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline Leformal, Andrew Cansfield, Svenja Burckhardt
-
Patent number: 7557244Abstract: The present invention relates to compounds having the general Formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, and R10 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: GrantFiled: April 20, 2007Date of Patent: July 7, 2009Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernadez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Chih Yung Ho, Yan Zhang
-
Publication number: 20090118289Abstract: The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: ApplicationFiled: October 21, 2005Publication date: May 7, 2009Applicant: CELLZOME AGInventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline Leformal, Andrew Cansfield, Svenja Burckhardt
-
Patent number: 7300930Abstract: The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ?O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula —N(RN)Q, wherein: RN is an amino substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptablType: GrantFiled: June 22, 2005Date of Patent: November 27, 2007Assignee: Cancer Research Technology LimitedInventors: Stephen Neidle, Richard John Harrison, Lloyd Royston Kelland, Sharon Michele Gowan, Martin Anthony Read, Anthony Reszka